Clinical trials: Glucagon
Blood Sugar; High, Overweight and Obesity
Glucagon Like Peptide 1 (GLP-1) Booster™ RCT Study
BACKGROUND GLP1 booster (GB) was designed to stimulate the endogenous production of GLP1, which in turn releases insulin, controls blood glucose level, suppresses appetite and thus helps people lose weight.
- Conditions
- Blood Sugar; High, Overweight and Obesity, Fat Loss, GLP-1
- Trial name
- RCT (NCT07141472)
- Testing
- GB
- Where
- United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Lawry Han
Type 1 Diabetes Mellitus
Glucagon Rescue of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes Treated With Volagidemab
This trial is designed to evaluate the effect of glucagon receptor antagonism by volagidemab (once weekly) on glucose recovery from hypoglycemia after treatment with glucagon in adults with type 1 diabetes.
- Trial name
- NCT06272695
- Testing
- Volagidemab
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- REMD Biotherapeutics, Inc.
STEMI - ST Elevation Myocardial Infarction, Glucagon-like Peptide-1
Plasma Glucagon-like Peptide-1 Levels and In-hospital Complications in ST-segment Elevation Myocardial Infarction
Glucagon-like peptide-1 (GLP-1), produced mainly in enteroendocrine cells, participates in energy homeostasis and glucose metabolism by regulating islet hormone secretion, gastrointestinal motility, and food intake, making GLP-1…
- Conditions
- STEMI - ST Elevation Myocardial Infarction, Glucagon-like Peptide-1, Bleeding, Complications
- Trial name
- NCT03314844
- Volunteers
- 564 people
- Sponsor
- Chinese PLA General Hospital
Non Alcoholic Fatty Liver Disease, Non Alcoholic Steatohepatitis
Glucose-induced Glucagon-like Peptide 1 (GLP-1) Secretion in NAFLD Patients Compared to Healthy Controls
The incretin effect is impaired in patients with type 2 diabetes mellitus (T2DM), thus GLP-1 receptor agonists are used for the treatment of T2DM.
- Trial name
- NCT01674972
- Testing
- Oral glucose tolerance test
- Where
- Switzerland
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Diabetic Kidney Disease, Type 1 Diabetes
Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes
The primary objective of this study is to determine the effects of semaglutide on change in albuminuria from baseline to 26 weeks in type 1 diabetes.
- Trial name
- RT1D (NCT05822609)
- Testing
- Semaglutide
- Where
- 4 sites in United States, Canada
- Volunteers
- 60 people
- Sponsor
- University of Washington
Microvascular Angina
Glucagon-like Peptide-1 and Coronary Microvascular Dysfunction in Women With Angina Pectoris and no Coronary Stenosis
The aim of the present study is to evaluate the effect of treatment with Liraglutide on the coronary microvasculature and angina symptoms, in overweight patients with microvascular dysfunction and angina pectoris but no coronary…
- Trial name
- GAP (NCT02602600)
- Testing
- Liraglutide
- Where
- Denmark
- Volunteers
- 33 people
- Sponsor
- Eva Prescott
Type 2 Diabetes Mellitus (T2DM), Atrial Fibrillation (AF)
Strict Weight Management Based on GLP-1 RA for Ablation Outcomes in Overweight or Obese Patients with T2DM and AF
Objective To compare, in patients with Type 2 Diabetes Mellitus (T2DM) and Atrial Fibrillation (AF) undergoing radiofrequency ablation (RFA), whether strict weight management and glycemic control based on Glucagon-like Peptide-1…
- Trial name
- NCT06660134
- Testing
- Glucagon-like peptide-1 receptor agonists (GLP 1 RA)
- Where
- China
- Volunteers
- 174 people
- Sponsor
- Shanghai Chest Hospital
Spinal Cord Injuries, Type 2 Diabetes
Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes
It is not known whether a new diabetes drug, semaglutide, is an effective treatment for type 2 diabetes for persons with spinal cord injury (SCI), a population at higher risk for this condition.
- Trial name
- NCT06706284
- Testing
- Semaglutide Injectable Product
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Marzieh Salehi
Type 2 Diabetes, Peripheral Vascular Disorder Due to Diabetes Mellitus
Efficacy and Safety of Liraglutide in Type 2 Diabetes With Lower Extremity Arterial Disease
Diabetic lower extremity arterial disease ( DLEAD ), is a common complication of type 2 diabetes. However, DLEAD remains less studied than other diabetic vascular complications; and only few randomised controlled trials (RCTs)…
- Trial name
- NCT04146155
- Testing
- Liraglutide+standard-of-care treatment, standard-of-care treatment
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Osteoarthritis (OA) of the Knee
Optimization of Obesity for Total Knee Replacement With Glucagon-like Peptide-1 Receptor Agonist
Studies have shown that obese patients undergoing total knee replacement (TKR) surgery face a higher risk of perioperative issues such as increased use of pain medication, surgical site infections, and the need for revision…
- Trial name
- NPO-OOPS-TKR (NCT06807970)
- Testing
- Glucagon-like peptide-1 receptor agonists (GLP 1 RA), Control (Standard treatment)
- Where
- Hong Kong
- Volunteers
- 54 people
- Sponsor
- The University of Hong Kong
Type 2 Diabetes Mellitus
Glucolipotoxicity and Type 2 Diabetes
Elevations of blood glucose and lipid are thought to be deleterious to the insulin secretory function of the pancreas. This is known as glucolipotoxicity. However, few studies have examined this in detail.
- Trial name
- NCT01375270
- Testing
- Glucotoxicity, Lipotoxicity
- Where
- Denmark
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Type 2 Diabetes, Obesity
Splanchnic Blood Redistribution After Incretin Hormone Infusion and Obesity Surgery
Obesity is a worldwide problem and leads to multiple metabolic and endocrinological problems. Bariatric surgeries are a growing field as a treatment choice for morbid obesity (BMI > 35 kg/m2).
- Trial name
- GIP-PET (NCT01880827)
- Testing
- Roux-en-Y, GIP-infusion, GLP-1
- Where
- Finland
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Turku University Hospital
Glucagon Like Peptide-1 (GLP-1, Delayed Gastric Emptying
GLP_1 RA Ultrasound Study
The purpose of the study is to determine whether patients taking GLP-1 RAs have increased residual (left behind), gastric (stomach), contents due to delayed gastric emptying when following standard preoperative fasting guidelines.
- Conditions
- Glucagon Like Peptide-1 (GLP-1, Delayed Gastric Emptying, Risk of Aspiration, Diabetes
- Trial name
- NCT06581120
- Testing
- Glucagon-Like Peptide-1 receptor agonists, Point of Care Gastric Ultrasound
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Type 2 Diabetes
Study to Evaluate HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study, which aims to provide data on the efficacy and safety of HDM1002 tablets in adults with type 2 diabetes mellitus (T2DM) inadequately…
- Trial name
- NCT07193459
- Testing
- HDM1002 200 mg, HDM1002 400 mg
- Where
- China
- Volunteers
- 360 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Healthy
Exploratory Study of Additional Use of Scopolamine Butylbromide, Glucagon or NPO-11 Following Single Dose of NPO-11 in Healthy Adult Men
The purpose of this study is to evaluate the safety and efficacy of the additional administration of scopolamine butylbromide, glucagon or NPO-11 following a single intragastric dose of NPO-11 during endoscopy in healthy adult…
- Trial name
- NCT00740324
- Testing
- NPO-11
- Where
- Japan
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Nihon Pharmaceutical Co., Ltd
Diabetes
Involvement of Extrapancreatic Factors on Gastrointestinal-mediated Glucose Disposal
We want to investigate the mechanisms of extrapancreatic effects on gastrointestinal-mediated glucose disposal. In order to do so we will perform oral glucose tolerance tests and isoglycemic intravenous glucose infusions in total…
- Trial name
- Px-GIGD (NCT02006459)
- Where
- Denmark
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University Hospital, Gentofte, Copenhagen
Type 2 Diabetes
Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes
The purpose of this study is to determine the optimal dose or doses of HM11260C, when administered once a week under the skin, to improve the control of blood sugar levels in patients with early-stage type 2 diabetes mellitus…
- Trial name
- NCT02057172
- Testing
- HM11260C, liraglutide
- Where
- United States
- Volunteers
- 254 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Hypopituitarism
Stimulation Test With Intranasal Glucagon for Corticotroph, Somatotroph and Antidiuretic Axes
The diagnosis of secondary hypoadrenalism and GH deficiency (GHD) often requires the performance of a dynamic test. The glucagon stimulation test (GST) is one of the options for evaluating hypothalamic-pituitary function…
- Trial name
- NCT05206149
- Testing
- Intranasal glugagon
- Where
- Italy
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- A.O.U. Città della Salute e della Scienza
Type 1 Diabetes
Closed-loop Control of Glucose Levels (Artificial Pancreas) for 15 Weeks in Adolescents and Adults With Type 1 Diabetes
Closed-loop strategy is composed of three components: glucose sensor to read glucose levels, insulin pump to infuse insulin and a dosing mathematical algorithm to decide on the required insulin dosages based on the sensor's…
- Trial name
- NCT02846857
- Testing
- 15-week intervention with sensor-augmented pump, 15-week intervention with single-hormone closed-loop, 15-week intervention with dual-hormone closed-loop
- Sponsor
- Institut de Recherches Cliniques de Montreal
Hypoglycemia
Pharmacokinetics and Pharmacodynamics of BIOD-961 vs. Marketed Glucagons
BIOD-961 is a dry powder formulation of glucagon intended for use in a device that mixes (reconstitutes) the powder with liquid to make it easier for users to treat patients with severe hypoglycemia.
- Trial name
- NCT02403648
- Testing
- BIOD-961, Lilly Glucagon, Novo Glucagon
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Biodel